174 related articles for article (PubMed ID: 24301760)
21. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
[TBL] [Abstract][Full Text] [Related]
22. [Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma].
Shi C; Qin H; Ding C; Sun Y; Lyu Y; Shi T
Zhonghua Zhong Liu Za Zhi; 2015 Feb; 37(2):123-7. PubMed ID: 25975689
[TBL] [Abstract][Full Text] [Related]
23. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
[TBL] [Abstract][Full Text] [Related]
24. BRAF overexpression is associated with BRAF V600E mutation in papillary thyroid carcinomas.
da Silva RC; de Paula HS; Leal CB; Cunha BC; de Paula EC; Alencar RC; Meneghini AJ; Silva AM; Gontijo AP; Wastowski IJ; Saddi VA
Genet Mol Res; 2015 May; 14(2):5065-75. PubMed ID: 26125698
[TBL] [Abstract][Full Text] [Related]
25. Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma.
Lu J; Gao J; Zhang J; Sun J; Wu H; Shi X; Teng L; Liang Z
Int J Clin Exp Pathol; 2015; 8(1):793-9. PubMed ID: 25755776
[TBL] [Abstract][Full Text] [Related]
26. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
[TBL] [Abstract][Full Text] [Related]
27. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
Sun J; Zhang J; Lu J; Gao J; Lu T; Ren X; Duan H; Liang Z
Int J Clin Exp Pathol; 2015; 8(11):15072-8. PubMed ID: 26823846
[TBL] [Abstract][Full Text] [Related]
29. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
30. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
[TBL] [Abstract][Full Text] [Related]
31. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
32. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer.
Niederer-Wüst SM; Jochum W; Förbs D; Brändle M; Bilz S; Clerici T; Oettli R; Müller J; Haile SR; Ess S; Stoeckli SJ; Broglie MA
Surgery; 2015 Jan; 157(1):119-25. PubMed ID: 25482468
[TBL] [Abstract][Full Text] [Related]
33. BRAF(V600E) mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma.
Jing FJ; Liang J; Liang ZY; Meng C; Long W; Li XY; Lin YS
Chin Med J (Engl); 2013 Aug; 126(16):3013-8. PubMed ID: 23981603
[TBL] [Abstract][Full Text] [Related]
34. Clinical implications of the extent of BRAF
Liu L; Chang JW; Jung SN; Park HS; Oh T; Lim YC; Koo BS
Oral Oncol; 2016 Nov; 62():72-77. PubMed ID: 27865374
[TBL] [Abstract][Full Text] [Related]
35. Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression.
Kim MH; Bae JS; Lim DJ; Lee H; Jeon SR; Park GS; Jung CK
Endocr Relat Cancer; 2014; 21(6):891-902. PubMed ID: 25266729
[TBL] [Abstract][Full Text] [Related]
36. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
[TBL] [Abstract][Full Text] [Related]
38. BRAF Testing in Multifocal Papillary Thyroid Carcinoma.
Kimbrell HZ; Sholl AB; Ratnayaka S; Japa S; Lacey M; Carpio G; Bhatia P; Kandil E
Biomed Res Int; 2015; 2015():486391. PubMed ID: 26448939
[TBL] [Abstract][Full Text] [Related]
39. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
40. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.
Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS
J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
